Please assess the completion status of the following clinical trial:

Trial Title: Lansoprazole for Subgroups of Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dyspeptic adult outpatients~* Characteristic dyspeptic symptoms according to Rome III criteria (bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning)~* Upper gastrointestinal endoscopy excluding structural diseases~Exclusion Criteria:~* aged less than 20 years old,~* organic lesions such as peptic ulcer, tumor of any kind, stricture or structural deformity, erosive esophagitis, or vasculopathy on endoscopy~* typical and predominant reflux symptoms (heartburn or acid regurgitation)~* comorbidity with malignancy, diabetes mellitus, liver cirrhosis, renal failure, or porphyria~* history of intra-abdominal surgery~* concurrent use of aspirin, non-steroidal anti-inflammatory drug or proton pump inhibitor~* history of allergy or severe side effects to lansoprazole~* pregnant or lactating women.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lansoprazole (Type: EXPERIMENTAL): lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo once daily for eight weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).